Early results for HERV suppressor in MS promising
Posted: Thu May 01, 2014 3:28 am
Multiple sclerosis patients dosed with a monoclonal antibody specific for human endogenous retrovirus (HERV) proteins in a small pilot trial showed signs that the drug helped and was safe, a researcher said here.
After 12 monthly doses of the GNbAC1 antibody, targeting the so-called MRV-Env protein, seven patients with established MS (mean age 55, mean Expanded Disability Scale Score 4.
showed stability in MRI brain lesion activity and no disability progression on average, according to Hervé Perron, PhD, of GeNeuro SA in Geneva, Switzerland, which is developing the drug........ Read More - http://www.ms-uk.org/bacteriaandviruses
After 12 monthly doses of the GNbAC1 antibody, targeting the so-called MRV-Env protein, seven patients with established MS (mean age 55, mean Expanded Disability Scale Score 4.
showed stability in MRI brain lesion activity and no disability progression on average, according to Hervé Perron, PhD, of GeNeuro SA in Geneva, Switzerland, which is developing the drug........ Read More - http://www.ms-uk.org/bacteriaandviruses